BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $70.00 price objective on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 152.34% from the stock’s current price. BBIO has […]
Primecap Management Co. CA lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 944,000 shares of the company’s stock after acquiring an additional 5,300 shares during the period. Primecap […]
Brokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) Target Price at $47.82 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $29.76, but opened at $30.49. BridgeBio Pharma shares last traded at $30.08, with a volume of 180,372 shares traded. Wall Street Analyst Weigh In Several brokerages have issued reports on BBIO. […]
Raymond James initiated coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research note issued to investors on Thursday, StockNewsAPI reports. The firm issued an outperform rating and a $45.00 price target on the stock. Other analysts have also recently issued reports about the stock. Citigroup lifted their price objective on shares […]